Lilly, Vir Biotechnology and GSK announced first patient dosed in expanded BLAZE-4 trial for COVID-19
On Jan. 27, 2021, Eli Lilly, Vir Biotechnology and GlaxoSmithKline announced a collaboration to evaluate a combination of…
-
-
Heat Biologics announced publication of additional preclinical COVID-19 vaccine results
On Jan. 27, 2021, Heat Biologics announced the publication of additional preclinical COVID-19 results in Frontiers in Immunology,…
-
REGEN-COV antibody cocktail Is active against SARS-CoV-2 variants identified in the UK and South Africa
On Jan. 27, 2021, researchers in Dr. David Ho’s Columbia University lab and Regeneron scientists announced they had…
-
Antibody infusions prevented acquisition of some HIV strains, NIH studies found
On Jan. 26, 2021, NIH researchers announced that an investigational anti-HIV antibody delivered intravenously once every eight weeks…
-
Abbott’s panbio rapid antigen test received CE Mark for asymptomatic screening and sample collection
On Jan. 26, 2021, Abbott announced it had received CE Mark for two new uses of its Panbioﾙ…
-
NIH launched database to track neurological symptoms associated with COVID-19
On Jan. 26, 2021, NIH researchers announced that a new database to collect information from clinicians about COVID-19-related…
-
Vaxart announced additional preclinical COVID-19 oral vaccine data and publication
On Jan. 26, 2021, Vaxart announced additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a…
-
Data showed Lilly’s neutralizing antibodies bamlanivimab and etesevimab reduced risk of COVID-19 hospitalizations and death by 70 percent
On Jan. 26, 2021, Eli Lilly announced that bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together…
-
BioReference Laboratories teamed-up with the NBA and NHL to provide players and staff with COVID-19 testing
On Jan. 26, 2021, BioReference Laboratories, an OPKO Health company, announced COVID-19 testing agreements for players and officials,…
-
Merck discontinued development of SARS-CoV-2/COVID-19 vaccine candidates
On Jan. 25, 2021, Merck announced that the company had discontinued development of its SARS-CoV-2/COVID-19 vaccine candidates, V590…
-
SARS-CoV-2 needs cholesterol to invade cells and form mega cells
On Jan. 25, 2021, HHMI investigators reported that cholesterol, the waxy compound better known for clogging arteries, helps…
-
PRINCIPLE found antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19
On Jan. 25, 2021, scientists at the University of Oxford reported that after reviewing interim analyses of both…
-
Nirmidas Biotech received FDA Emergency Use Authorization for its COVID-19 rapid antibody fingerstick test
On Jan. 25, 2021, Nirmidas Biotech announced its second FDA Emergency Use Authorization (EUA) for their COVID-19 rapid…
-
Full-dose blood thinners decreased need for life support and improved outcome in COVID-19 patients
On Jan. 22, 2021, the NIH announced that in large clinical trial conducted worldwide, full dose anti-coagulation (blood…
-
COVAX announced new agreement, plans for first deliveries
On Jan. 22, 2021, COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for…
-
Pfizer and BioNTech reached agreement with COVAX for advance purchase of vaccine to combat COVID-19
On Jan. 22, 2021, Pfizer and BioNTech announced an advance purchase agreement with COVAX for up to 40…
-
NIH researchers identified new genetic disorder that affects brain, craniofacial skeleton
On Jan. 21, 2021, researchers at the NIH announced they had discovered a new genetic disorder characterized by…
-
NIH study compares low-fat, plant-based diet to low-carb, animal-based diet
On Jan. 21, 2021, the National Institutes of Health announced results of a small but highly controlled study…
-
FDA approved first extended-release, injectable drug regimen for adults living with HIV
On Jan. 21, 2021, the FDA approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for…
-
The US Department of Defense recommended adults 75 and older should seek COVID-19 vaccine
On Jan. 21, 2021, the U.S. Department of Defense (DOD) recommended that adults ages 75 and older should…
-
A closer look at T cells revealed big differences in mild vs severe COVID-19 cases
On Jan. 21, 2021, NIH researchers announced that after people recover from infection with a virus, the immune…
-
Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
On Jan. 21, 2021, Eli Lilly announced that bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19…
-
VBI Vaccines announced progress of Coronavirus vaccine program
On Jan. 21, 2021, VBI Vaccines announced that it expected to initiate the first Phase 1/2 clinical study…
-
Janssen announced FDA approval of CABENUVA, the first long-acting HIV treatment regimen
On Jan. 21, 2021, Janssen Pharmaceutical announced the FDA had approved CABENUVA (consisting of Janssenﾒs rilpivirine and ViiV…
-
Patients in cancer remission at high risk for severe COVID-19 illness
On Jan. 21, 2021, Penn Medicine reported that patients with inactive cancer and not currently undergoing treatments also…
-
XBiotech candidate True Humanﾙ COVID-19 therapy found to target highly infectious emerging strain
On Jan. 21, 2021, XBiotech announced that its COVID-19 candidate True Humanﾙ antibody therapy may also be used…
-
Mesa Biotech received 510(k) clearance and CLIA waiver for Its Accula Strep A Molecular Point of Care Test
On Jan. 19, 2021, Mesa Biotech announced it had received 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA)…
-
Heat Biologics commenced manufacturing process for ZVX-60
On Jan. 19, 2021, Heat Biologics announced it had transferred its gp96-based COVID-19 vaccine cell line (“ZVX-60”) to…
-
Pfizer and BioNTech published results of study showing COVID-19 vaccine antibodies neutralized UK strain
On Jan. 19, 2021, Pfizer and BioNTech announced that results from an in vitro study that provided additional…
-
INEOS donated ﾣ100 million to create new Oxford University institute to fight antimicrobial resistance
On Jan. 19, 2021, a new state of the art institute for antimicrobial research iwasa announced at Oxford…
